Author

G. ren

Observed names: G.Z. Ren, Guizhi Ren

Institution: Gaozhou People's Hospital

Observed institutions: Shandong First Medical University, Gaozhou People's Hospital

ORCID: 0009-0007-0476-7398

Observed ORCID: 0009-0007-0476-7398

OpenAlex ID: A5017269790

Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database

2025 · Shiqiao Wang, Guizhi Ren, et al. · BMC Pharmacology and Toxicology · 4

389P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial

2024 · H. Li, D. Zhou, et al. · Annals of Oncology

444P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial

2023 · H. Li, D. Zhou, et al. · Annals of Oncology

P1321 Long Term Outcomes and Prognostic Analysis of Small Hepatocellular Carcinoma Treated With Radiofrequency Ablation: 10 Years Follow up in Chinese Patients

2014 · L. Zhang, Y. Chen, et al. · Journal of Hepatology

Works count: 4

Citation count: 4

H-index: 1

I10-index: